Recombinant Human Proprotein Convertase 9/PCSK9 Protein, CF

When Recombinant Human LDL R (Catalog # 2148-LD) is coated at 2 μg/mL, Recombinant Human Proprotein Convertase9/PCSK9 (Catalog # 3888-SE) binds with an ED50 of 70‑420 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Proprotein Convertase 9/PCSK9 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LDL R (Catalog # 2148-LD) is coated at 2 µg/mL, Recombinant Human Proprotein Convertase 9/PCSK9 binds with an ED₅₀ of 70-420 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human Proprotein Convertase 9/PCSK9 protein
  Gln31-Gln152 & Ser153-Gln692, with a C-terminal 10-His tag
• Accession #: Q8NBP7
• N-terminal Sequence: Ser153 (mature form); No results obtained for pro domain, Gln31 inferred from enzymatic pyroglutamate treatment revealing Glu32
• Structure / Form: Mature form & pro domain
• Protein/Peptide Type: Recombinant Enzymes
• Gene: PCSK9
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 14 kDa & 59 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 19 kDa & 66 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Proprotein Convertase 9/PCSK9 Protein, CF

• EC 3.4.21
• EC 3.4.21.111
• FH3
• FH3neural apoptosis regulated convertase 1
• FHCL3
• HCHOLA3
• hypercholesterolemia, autosomal dominant 3
• LDLCQ1
• NARC1
• NARC-1
• NARC-1convertase subtilisin/kexin type 9 preproprotein
• NARC1EC 3.4.21.-
• Neural apoptosis-regulated convertase 1
• PC9
• PCSK9
• Proprotein Convertase 9
• proprotein convertase subtilisin/kexin type 9
• Subtilisin/kexin-like protease PC9

Background

The human PCSK9 gene encodes Proprotein Convertase 9 (PC9), which is also known as Neural Apoptosis Regulated Convertase 1 (NARC1) (1). The deduced amino acid sequence of human PCSK9 consists of a signal peptide (residues 1 to 30), a pro peptide (residue 31 to 152), and a mature chain (residues 153 to 692) that contains a serine protease domain (residues 161 to 431) found in members of the furin/PC family. PCSK9 protease activity may be limited, since it has only been demonstrated through its own autocatalytic processing (2). After the autocleavage in the ER, the pro domain and mature chain exit the cell together through non‑covalent interactions (3). PCSK9 is a key regulator of LDL-cholesterol levels (LDL-C) through binding of the LDL receptor, resulting in the reduction of receptor recycling to the cell surface and the acceleration of receptor degradation in lysosomes (3). Both gain of function (GOF) and loss-of-function (LOF) mutations have been found in the PCSK9 gene (3). GOF mutations are linked to familial autosomal dominant hypercholesterolemia, a disease characterized by elevated plasma levels of LDL-C. In comparison, LOF mutations lead to low levels of LDL-C and protection against coronary heart disease.

1. Seidah, N.G. et al. (2003) Proc. Natl. Acad. Sci. USA 100:928.
2. Naureckiene, S. et al. (2003) Arch. Biochem. Biophys. 420:55.
3. Costet, P. et al. (2008) Trends Biochem. Sci. 33:426.

Publications for Proprotein Convertase 9/PCSK9 (3888-SE)(2)

Publications using 3888-SE

• Fowler, A;Van Rompay, KKA;Sampson, M;Leo, J;Watanabe, JK;Usachenko, JL;Immareddy, R;Lovato, DM;Schiller, JT;Remaley, AT;Chackerian, B; A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates bioRxiv : the preprint server for biology 2023-05-15 [PMID: 37292981] (ELISA Capture, Primate - Macaca fascicularis (Cynomolgus Macaques))
• Rashid S, Tavori H, Brown P, Linton M, He J, Giunzioni I, Fazio S Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation, 2014-05-23;130(5):431-41. 2014-05-23 [PMID: 25070550] (Bioassay, Western Blot, Human)

Bioinformatics

• Gene Symbol: PCSK9
• Uniprot:
  • Q8NBP7()